New perspectives on metabolic imaging in the management of prostate cancer in 2022: A focus on radiolabeled PSMA-PET/CT (Review)

被引：1

作者：

Simon, Helene ^{[1
]}

Henkel, Daniel ^{[2
]}

Chiron, Paul ^{[3
]}

Helissey, Carole ^{[1
]}

机构：

[1] Mil Hosp Begin, Dept Oncol, Clin Res Unit, 69 Ave Paris, F-94160 St Mande, France

[2] Univ Paris 8 Vincennes St Denis, Un Format & Rech 5, F-93200 Paris, France

[3] Mil Hosp Begin, Dept Urol, F-94160 St Mande, France

来源：

MOLECULAR AND CLINICAL ONCOLOGY | 2023年 / 19卷 / 01期

关键词：

metabolic imaging; PET-PSMA; prostate cancer; GA-68-PSMA-11; PET/CT; MEMBRANE ANTIGEN; CLINICAL UTILITY; LIGAND; ADENOCARCINOMA; METASTASIS; THERAPY; IMPACT; PSA;

D O I：

10.3892/mco.2023.2647

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Nuclear medicine is an essential part of prostate cancer management concerning initial staging, patient follow-up and even therapy. Prostate-specific membrane antigen (PSMA) is a glutamate carboxypeptidase II transmembrane glycoprotein expressed by 80% of prostatic cells. The interest in this protein is due to its specificity for prostatic tissue. The use of 68GaPSMA PET/CT in the context of disease staging is thus well-established and recommended, especially for high-risk disease with metastases and lymph node involvement. However, the risk of false positives raises questions regarding its place in the management of patients with prostate cancer. The present study aimed to determine the use of PET-PSMA in the care of patients with prostate cancer but also to assess its limits of use.

引用

页数：11

共 66 条

[1] Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer [J].

Afshar-Oromieh, Ali ;

Zechmann, Christian M. ;

Malcher, Anna ;

Eder, Matthias ;

Eisenhut, Michael ;

Linhart, Heinz G. ;

Holland-Letz, Tim ;

Hadaschik, Boris A. ;

Giesel, Frederik L. ;

Debus, Juergen ;

Haberkorn, Uwe .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 (01) :11-20

[2] Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study [J].

Ahmed, Hashim U. ;

Bosaily, Ahmed El-Shater ;

Brown, Louise C. ;

Gabe, Rhian ;

Kaplan, Richard ;

Parmar, Mahesh K. ;

Collaco-Moraes, Yolanda ;

Ward, Katie ;

Hindley, Richard G. ;

Freeman, Alex ;

Kirkham, Alex P. ;

Oldroyd, Robert ;

Parker, Chris ;

Emberton, Mark .

LANCET, 2017, 389 (10071) :815-822

[3] Regional Lymph Node Metastasis on Prostate Specific Membrane Antigen Positron Emission Tomography Correlates with Decreased Biochemical Recurrence-Free and Therapy-Free Survival after Radical Prostatectomy: A Retrospective Single-Center Single-Arm Observational Study [J].

Amiel, Thomas ;

Wurnschimmel, Christoph ;

Heck, Matthias ;

Horn, Thomas ;

Nguyen, Noemi ;

Budaeus, Lars ;

Knipper, Sophie ;

Wenzel, Mike ;

Rauscher, Isabel ;

Eiber, Matthias ;

Wang, Hui ;

Maurer, Tobias .

JOURNAL OF UROLOGY, 2021, 205 (06) :1663-1670

[4] Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol [J].

Calais, Jeremie ;

Zhu, Shaojun ;

Hirmas, Nader ;

Eiber, Matthias ;

Hadaschik, Boris ;

Stuschke, Martin ;

Herrmann, Ken ;

Czernin, Johannes ;

Kishan, Amar U. ;

Nickols, Nicholas G. ;

Elashoff, David ;

Fendler, Wolfgang P. .

BMC CANCER, 2021, 21 (01)

[5] Phase III randomized trial of PSMA PET prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: Study protocol NCT04457245. [J].

Calais, Jeremie ;

Zhu, Shaojun ;

Hirmas, Nader ;

Eiber, Matthias ;

Hadaschik, Boris A. ;

Stuschke, Martin ;

Herrmann, Ken ;

Czernin, Johannes ;

Kishan, Amar Upadhyaya ;

Nickols, Nicholas George ;

Elashoff, David ;

Fendler, Wolfgang Peter .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)

[6] Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT] [J].

Calais, Jeremie ;

Czernin, Johannes ;

Fendler, Wolfgang P. ;

Elashoff, David ;

Nickols, Nicholas Nicholas G. .

BMC CANCER, 2019, 19 (1)

[7] Potential Impact of 68Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer [J].

Calais, Jeremie ;

Kishan, Amar U. ;

Cao, Minsong ;

Fendler, Wolfgang P. ;

Eiber, Matthias ;

Herrmann, Ken ;

Ceci, Francesco ;

Reiter, Robert E. ;

Rettig, Matthew B. ;

Hegde, John V. ;

Shaverdian, Narek ;

King, Chris R. ;

Steinberg, Michael L. ;

Czernin, Johannes ;

Nickols, Nicholas G. .

JOURNAL OF NUCLEAR MEDICINE, 2018, 59 (11) :1714-1721

[8] Impact of 68Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence [J].

Calais, Jeremie ;

Fendler, Wolfgang P. ;

Eiber, Matthias ;

Gartmann, Jeannine ;

Chu, Fang-I ;

Nickols, Nicholas G. ;

Reiter, Robert E. ;

Rettig, Matthew B. ;

Marks, Leonard S. ;

Ahlering, Thomas E. ;

Huynh, Linda M. ;

Slavik, Roger ;

Gupta, Pawan ;

Quon, Andrew ;

Allen-Auerbach, Martin S. ;

Czernin, Johannes ;

Herrmann, Ken .

JOURNAL OF NUCLEAR MEDICINE, 2018, 59 (03) :434-441

[9] Detection of Brain Metastasis With 68Ga-Labeled PSMA Ligand PET/CT A Novel Radiotracer for Imaging of Prostate Carcinoma [J].

Chakraborty, Partha Sarathi ;

Kumar, Rajiv ;

Tripathi, Madhavi ;

Das, Chandan Jyoti ;

Bal, Chandrasekhar .

CLINICAL NUCLEAR MEDICINE, 2015, 40 (04) :328-329

[10]

EAU Guidelines, 2022, EAU ANN C

← 1 2 3 4 5 6 7 →